Nanoliposome Peptide Vaccine Shrinks HER2-Positive Breast Tumors in Mice

The Lip-DOPE-MPL-GP2 formulation generated the highest IFN-γ+ CD8+ T cell and cytotoxic T lymphocyte responses among all tested formulations, as measured by ELISpot and flow cytometry. In both prophylactic (vaccination before tumor challenge) and therapeutic (vaccination after tumor establishment) experiments, mice immunized with this formulation had smaller tumors and longer survival compared to other groups. The combination of DOPE (fusogenic lipid) and MPL (adjuvant) was key to both the immune response and anti-tumor efficacy.

GP2 peptide was conjugated to maleimide-mPEG2000-DSPE micelles and post-inserted into liposomes containing DMPC, DMPG, DOPE, and MPL. BALB/c mice were immunized with various formulations. Immune responses were evaluated by ELISpot and intracellular cytokine flow cytometry. Anti-tumor efficacy was tested in both prophylactic and therapeutic TUBO xenograft models measuring tumor size and survival.

GP2 is a HER2-derived peptide already in human clinical trials as a breast cancer vaccine. This study shows that delivering it via nanoliposomes dramatically enhances the immune response compared to standard vaccine formulations. If this improved delivery translates to humans, it could make peptide-based cancer vaccines far more effective for the approximately 15-20% of breast cancers that overexpress HER2.

Peptide-based cancer vaccines have struggled with weak immune responses when delivered using traditional methods. Nanoliposome delivery that combines targeted antigen presentation (GP2 peptide), enhanced cell entry (fusogenic DOPE lipid), and immune activation (MPL adjuvant) represents a sophisticated platform approach that could be applied beyond breast cancer to any peptide vaccine target.

This is a mouse study using a xenograft model, which may not accurately predict human immune responses or therapeutic outcomes. The TUBO model is a specific mouse breast cancer system that may differ from human HER2-positive tumors. Specific tumor size reductions and survival data are not quantified in the abstract. Long-term efficacy and safety in larger animal models or humans have not been assessed.